Bli medlem
Bli medlem

Du är här


Prothena Corporation plc: Prothena Announces Appointment of Chief Commercial Officer

DUBLIN, Ireland, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein
immunotherapies, announced today the appointment of David B. McNinch as Chief
Commercial Officer.

The creation of this new senior management position with responsibility for
shaping and delivering an integrated global commercial strategy reflects
Prothena's continuing evolution from a development stage company to an
integrated commercial organization.

"David has an extensive commercial background that spans pharmaceutical and
biotech companies, including global commercial launch experience across
multiple therapeutic areas in both large and rare diseases," said Dale
Schenk, PhD, President and Chief Executive Officer of Prothena. "David joins
Prothena at a time when we are beginning to plan for the commercialization of
our lead clinical compound NEOD001 for the potential treatment of patients
with AL amyloidosis. We are pleased to welcome him to Prothena and look
forward to having his strategic commercial leadership strengthen our
management team."

Mr. McNinch is a seasoned biotechnology executive with more than 20 years of
experience of commercializing new therapies. Prior to joining Prothena, Mr.
McNinch was Senior Vice President of Commercial Operations at InterMune
Pharmaceuticals, Inc. where he was responsible for building the US Commercial
infrastructure and successfully launching Esbriet® (pirfenidone), until
InterMune was acquired by Roche. Prior to InterMune, Mr. McNinch was Vice
President of Marketing and Managed Markets for Ipsen, Inc., and has held
various senior sales and marketing positions at Affymax, Genentech, Novartis
and AstraZeneca.

Mr. McNinch earned his BS in Marketing from the University of South Carolina.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company
focused on the discovery, development and commercialization of novel protein
immunotherapies for the potential treatment of diseases that involve amyloid
or cell adhesion. The company is developing antibody-based product candidates
that target a number of potential indications including AL amyloidosis
(NEOD001), Parkinson's disease and other related synucleinopathies (PRX002),
and psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the company's web site at

Forward-looking Statements

This press release contains forward-looking statements. These statements
relate to, among other things, our contemplated commercialization of NEOD001;
and our expectations regarding our Chief Commercial Officer's contributions
to Prothena. These statements are based on estimates, projections and
assumptions that may prove not to be accurate, and actual results could
differ materially from those anticipated due to known and unknown risks,
uncertainties and other factors, including but not limited to the risks,
uncertainties and other factors described in the "Risk Factors" sections of
our Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC) on March 13, 2015, our subsequent Quarterly Reports on Form
10-Q filed with the SEC and our Annual Report on Form 10-K for fiscal year
2015 to be filed with the SEC. Prothena undertakes no obligation to update
publicly any forward-looking statements contained in this press release as a
result of new information, future events or changes in Prothena's
Investors: Tran Nguyen, CFO

Media: Ellen Rose


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.